Cyclenium Pharma and Haplogen GmbH have signed a research agreement for the discovery of novel pharmaceutical candidates in multiple disease areas. The collaboration combines two next-gen drug discovery platforms: Cyclenium’s CMRT Technology-derived QUEST Library and associated hit-to-lead optimization, with Haplogen’s haploid genetics technology and expertise in host target identification, validation and screening. The companies will initially focus on certain anti-viral Haplogen ta...